PLoS Pathogens (Mar 2007)

Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV.

  • Anneleen Hombrouck,
  • Jan De Rijck,
  • Jelle Hendrix,
  • Linos Vandekerckhove,
  • Arnout Voet,
  • Marc De Maeyer,
  • Myriam Witvrouw,
  • Yves Engelborghs,
  • Frauke Christ,
  • Rik Gijsbers,
  • Zeger Debyser

DOI
https://doi.org/10.1371/journal.ppat.0030047
Journal volume & issue
Vol. 3, no. 3
p. e47

Abstract

Read online

Retroviruses by definition insert their viral genome into the host cell chromosome. Although the key player of retroviral integration is viral integrase, a role for cellular cofactors has been proposed. Lentiviral integrases use the cellular protein LEDGF/p75 to tether the preintegration complex to the chromosome, although the existence of alternative host proteins substituting for the function of LEDGF/p75 in integration has been proposed. Truncation mutants of LEDGF/p75 lacking the chromosome attachment site strongly inhibit HIV replication by competition for the interaction with integrase. In an attempt to select HIV strains that can overcome the inhibition, we now have used T-cell lines that stably express a C-terminal fragment of LEDGF/p75. Despite resistance development, the affinity of integrase for LEDGF/p75 is reduced and replication kinetics in human primary T cells is impaired. Detection of the integrase mutations A128T and E170G at key positions in the LEDGF/p75-integrase interface provides in vivo evidence for previously reported crystallographic data. Moreover, the complementary inhibition by LEDGF/p75 knockdown and mutagenesis at the integrase-LEDGF/p75 interface points to the incapability of HIV to circumvent LEDGF/p75 function during proviral integration. Altogether, the data provide a striking example of the power of viral molecular evolution. The results underline the importance of the LEDGF/p75 HIV-1 interplay as target for innovative antiviral therapy. Moreover, the role of LEDGF/p75 in targeting integration will stimulate research on strategies to direct gene therapy vectors into safe landing sites.